Liquidia Corporation Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Liquidia Corporation Common Stock trades at $33.46 (market cap $2.40B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.86 (market cap $17.70B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 7.4× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is more actively traded (2,857,547 versus 2,181,370). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| LQDA | USIG | |
|---|---|---|
Market Cap | $2.40B | $17.70B |
Volume | 2,857,547 | 2,181,370 |
Sector | Health | Fixed Income |
52-Week High | $91.03 | $52.69 |
52-Week Low | $22.02 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The ETF maintains regular dividend distributions, with recent payments of $0.20-0.21 per share.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in its credit quality. Key risks include bond market volatility and credit spread fluctuations. Current technical weakness warrants caution despite the neutral sentiment from oscillators and institutional buying interest.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →